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Available online 25 November 2016MicroRNAs (miRNAs) are endogenously initiated, small non-coding RNAs and typically regulate
the expression of mRNAs in post transcriptional level either via translational repression or
mRNA degradation. Aberrant expression of miRNAs is observed in diverse disease and altered
physiological states. Recently, it has been revealed that miRNAs are not only present in cells
but also in extracellular milieu especially in different bio-ﬂuids including blood plasma, follicu-
lar ﬂuid and even in cell culture media. Such extracellular miRNAs (ECmiRNAs) are remarkably
stable in the extracellular harsh environment with the presence of high RNAse activity.
Although the precise mechanisms of release of cellular miRNAs to extracellular environment
remain largely unknown, recent studies suggest that the expression of these ECmiRNAs can
be associated with patho-physiological condition of an organism. Moreover, these ECmiRNAs
may deliver to the recipient cells via certain pathways where they can regulate translational
activity of target genes. This review will discuss the nature and stability of ECmiRNAs along
with their release mechanisms. Furthermore, based on recent evidences, it also summarizes
the possible function of these ECmiRNAs in distant cell-to-cell communication and the difﬁcul-
ties we may face during ECmiRNA research.
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MicroRNA (miRNA) and Their Biogenesis
miRNAs are mostly studied small non-coding RNAs, which are typically 18–24 nucleotides long and are considered as one of
the major post-transcriptional regulators of gene expression. This process is accomplished through binding of miRNA to their tar-
get mRNAs by base-pairing and subsequently inducing either translational repression or mRNA destabilization. They are estimated
to comprise 1–5% of animal genes, and thousands of miRNAs can be encoded by a genome at a time (Hossain et al., 2012). Bio-
informatics analysis estimated that more than 60% of mRNAs in mammalian genome can be targeted by single miRNA. Because of
their broader targeting characteristics, miRNAs are expected to be involved in most biological pathways and cellular processes in-
cluding cell proliferation, apoptosis, cellular development and cellular signaling. Upon its discovery in Caenorhabditis elegans in the
early 1990s (Lee et al., 1993), since then, miRNA has been identiﬁed in a wide range of biological pathways of different organisms,
ranging from single-cell algae to multi-cellular mammalians, indicating their function is an ancient and critical cellular regulatory
mechanism. According to miRbase (version) there are more than 2000 known human miRNAs that have been identiﬁed to inﬂu-
ence gene expression and associated with pathological conditions.
The biogenesis of miRNAs is tightly regulated spatio-temporal process, and any deviation is associated with several diseases.
The cellular process of miRNA biogenesis involves both nuclear and cytoplasmic processes (Lee et al., 2002). MiRNAs originate
from large primary (pri) and precursor (pre) transcripts which undergo successive multi-steps of processing until they reach
their mature and functional form (Fig. 1). All miRNAs are transcribed by RNA polymerase II from chromosomal DNA (intergenicFig. 1. miRNA biogenesis and release of miRNAs in the extracellular environment. Pri-miRNAs are transcribed by RNA polymerase II and later processed by Drosha
to Pre-miRNA. Exportin5 transfer these Pre-miRNAs from nucleus to cytoplasm where Dicer processed them into mature miRNAs. Mature miRNAs can be selec-
tively incorporated into the exosomes or coupled with Ago2 protein and released in to extracellular milieu. Alternatively, they can be enwrapped with
microvesicles or attached to HDL and later released to extracellular environment.
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et al., 2004). A microprocessor complex consists of Drosha and DGCR8 further processes the resulting pri-miRNAs in to a ∼70 nu-
cleotide long double stranded stem-loop hair-pin like structure called precursor miRNA (pre-miRNA) (Landthaler et al., 2004; Lee
et al., 2003). These excited pre-miRNA hairpins are actively transported from nucleus to the cytoplasm by Exportin-5 complexed
with Ran-GTPase (Yi et al., 2003) where they further cleaved into ~22 bp miRNA/miRNA* duplexes by Dicer/TRBP enzyme com-
plex (Chendrimada et al., 2005; Zhang et al., 2002). In the ﬁnal step, miRNA/miRNA* duplexes separate from each other and sub-
sequently one strand (guide strand) incorporated with Argonaute (AGO) protein of RNA-induced silencing complex (RISC) and
forms miRISC whereas the other strand (passenger strand) is supposed to be degraded normally in the cytoplasm (Ender and
Meister, 2010; Okamura et al., 2004). This mature miRNA strand incorporated with RISC sequence speciﬁcally binds to their com-
plementary mRNAs, promoting their degradation or translational inhibit (Fig. 1).
Extracellular miRNA (ECmiRNA)
While majority of miRNAs are detected in cellular microenvironment, surprisingly a handful number of miRNAs, commonly
known as circulating miRNA or extracellular miRNA, have also been detected in extracellular environment, including different bi-
ological ﬂuids (Fig. 2) and cell culture media (Hunter et al., 2008; Mitchell et al., 2008; Valadi et al., 2007). Recent studies showed
that miRNAs are not only present in serum (Chen et al., 2008; Noferesti et al., 2015) or plasma (Arroyo et al., 2011; Chim et al.,
2008) but also in different extracellular bio-ﬂuids including saliva, tears, urine, breast milk, colostrum, peritoneal ﬂuid, cerebrospi-
nal ﬂuid, bronchial lavage and seminal ﬂuid (Weber et al., 2010) and follicular ﬂuid (da Silveira et al., 2012; Sang et al., 2013;
Sohel et al., 2013). Moreover, the expression proﬁle of ECmiRNAs from different types of bio-ﬂuids in relation to different path-
ophysiological conditions shows a speciﬁc pattern which indicating that extra-cellular miRNAs may not be passively released from
the necrotic or injured cells rather selectively released from the cells (Mar-Aguilar et al., 2013; Noferesti et al., 2015).
Unique Characteristics of ECmiRNAs
In contrast to cellular miRNAs and other RNA species, which are degraded in extracellular environment within few seconds,
ECmiRNAs are remarkably stable and can survive under unfavorable conditions for long time. When synthetic miRNAs spiked
into human plasma, it shows rapid degradation (within few seconds). While denaturing solution inactivated RNase activity in
plasma or serum, the exogenous miRNAs get released from degradation (Mitchell et al., 2008). Thus, it is clear that synthetic
miRNA species are vulnerable and susceptible to quick degradation in plasma or any other bio-ﬂuids, whereas ECmiRNAs are re-
sistant to high endogenous RNase activity, suggesting that these miRNAs are adopting some protective mechanisms to bypass
high RNase activity in the extracellular environment. Some reports showed that ECmiRNAs in body ﬂuids remain stable evenFig. 2. ECmiRNAs found in different bio-ﬂuids so far. ECmiRNAs have been detected in almost all biological ﬂuids including blood serum/plasma, cerebrospinal
ﬂuids, peritoneal ﬂuid, amniotic ﬂuid synovial ﬂuid, follicular ﬂuid, breast milk, colostrum, tears and urine. Interestingly, the expression pattern of some of miRNAs
in these ﬂuids directly reﬂect the patho-physiological condition of an organism.
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most of cellular RNAs were degraded quickly (Gilad et al., 2008; Taylor and Gercel-Taylor, 2008). In addition, other studies dem-
onstrated that miRNAs in serum are still detectable and gives speciﬁc expression pattern in quantitative PCR (qPCR) after being
subjected to incubation at room temperature for 24 h (Mitchell et al., 2008) and maximum 10 freeze–thaw cycle (Chen et al.,
2008). Furthermore, ECmiRNAs present in serum are resistant against RNase A compared to other endogenous RNA species
such as 28s rRNA, 18s rRNA, β-actin, GAPDH and U6 (Chen et al., 2008). Most of these ECmiRNAs derived from serum showed
considerable level of expression after 3 h or even overnight incubation with RNase-A, however following the same RNase-A treat-
ments all large RNAs were degraded (Chen et al., 2008).
The mechanism underlying the remarkable stability of ECmiRNAs in the RNase-rich environment of blood and other bio-ﬂuids
are not well understood. Many hypotheses have been proposed to explain the possible mechanisms through which RNAs and
miRNAs are released and protected from endogenous RNase activity in circulation. One of the earliest theories suggested that
RNAs might be conjugated with protein which would later protect them from both DNase and RNase activity (Sisco, 2001). How-
ever, later on it has been shown that RNA species present in plasma are protected from degradation probably due to inclusion in
lipid or lipoprotein complexes, not by binding with DNA (El-Hefnawy et al., 2004). Another hypothesis is that miRNAs are
wrapped with membrane vesicles (exosomes, microparticles and apoptotic bodies) that shad miRNAs in extracellular environ-
ment and protect them from RNase activity. On the other, some studies have shown that, after isolating exosome/microvesicles
using high-speed ultracentrifugation from culture media (Turchinovich et al., 2011) or serum (Noferesti et al., 2015) or follicular
ﬂuid (Sohel et al., 2013), a handful number of miRNAs are still detectable in the microvesicles free fraction, suggested that the
presence of non-vesicle associated miRNA (might be miRNA-protein or miRNA-lipid/lipoprotein complexes) in extra-cellular ﬂuid.
Possible Ways to Release ECmiRNAs
Although several studies conﬁrmed the presence of ECmiRNAs in various bio-ﬂuids, the mechanisms which are responsible for
the release of these miRNAs in extracellular environment remained an unsolved puzzle for quite a long period. There are argu-
ments and theories to explain how these miRNAs released in extracellular body ﬂuids and serves cell–cell communications.
One of the earliest assumptions of miRNA release and remarkable stability in extracellular environment is they might be protected
by enwrapping into membrane vesicles (i.e. exosomes, microvesicles). This theory emerged after Valadi et al. showed exosomes
can carry a functional miRNA population and Hunter et al. detected miRNAs in peripheral blood microvesicles (Hunter et al.,
2008). These two ﬁndings led to a revolutionary theory — existence and transportation of miRNAs can be mediated through ves-
icles. Later on, increasing number of studies have demonstrated that the transfer of protein, mRNA and miRNA in different body
ﬂuids can be mediated via exosomes, microvesicles and apoptotic bodies that are released from a variety of cell types to modulate
cell proliferation/apoptosis, angiogenesis, tumor cell invasion and cell–cell communication. In 2011, the theory “vesicle encapsu-
lated existence and transport of miRNA” was hugely challenged when two independent studies showed that 90% ECmiRNAs are
associated with Ago protein family in both blood plasma and cell culture media (Arroyo et al., 2011; Turchinovich et al., 2011).
However, ECmiRNAs coupled with Ago protein family found to be non-speciﬁc product resulting from physiological activity
and death of cells (Turchinovich et al., 2012). Since then, increasing number of studies have consistently showed that ECmiRNAs
can be released and shaded from extracellular harsh environment through a) exosomes b) microvesicles c) apoptotic bodies
d) high density lipoprotein (HDL) and e) AGO protein complex. The release mechanisms of ECmiRNAs are graphically presented
in Fig. 1.
Release and Transport of ECmiRNA Through Exosomes
Exosomes are homologous membrane bound small vesicles (50–90 nm) of endosomal origin (Camussi et al., 2010; Cheng
et al., 2014) and are present in almost all biological ﬂuids. The main components of exosome membrane are lipid and protein
which enriched with lipid rafts (Mathivanan et al., 2010). Exosomes are formed by internalization of the cell membrane to pro-
duce endosomes. Invagination of the membrane of endosomes results several intraluminal vesicles, these organelles are known as
multivesicular bodies (Urbé et al., 2003). Budding of endosomes occurs in response to different cellular stimulations. This process
largely depends on calcium inﬂux, calpain and cytoskeleton reorganization (Johnstone, 2006). Accumulating evidences suggesting
that these vesicles can function as intercellular transmitters to convey their contents, in particular miRNA, from one cell to anoth-
er (Rechavi et al., 2009; Skog et al., 2008; Valadi et al., 2007). Formation and release of exosomes by cells is a complex and co-
ordinated process which require enzymatic activation and energy (ATP) (Yáñez-Mó et al., 2015), and miRNA proﬁles of
exosomes derived from bio-ﬂuids and culture media mostly differ from their parent cells. Therefore, it is logical to think that
cell may possess an active selection mechanism for exosomes and their content. Exosomes can carry a wide variety of molecules
including lipids, proteins, DNAs, mRNAs and miRNAs (Simpson et al., 2012), among them miRNAs got the research priority be-
cause of their diversiﬁed functions and implications.
In the very ﬁrst study that describe the exosome mediated transfer of miRNAs, Valadi et al. reported exosomes released from
human and murine bone marrow-derived mast cells contain mRNA and miRNA, which are transferrable to other human or mouse
mast cells. When exosomes from mouse mast cells transferred to human mast cells, they produce new mouse protein in recipient
cells, indicating that the exosomal mRNAs are functional and they can be translated after entering into another cell (Valadi et al.,
2007). Subsequently, numerous studies were conducted to investigate the functional relevance of exosomal ECmiRNAs. Epstein–
Barr virus (EBV)-infected cells released exosomes contain ECmiRNAs and peripheral blood mononuclear cells can up take these
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infection in mammary gland, milk exosomes are loaded with 14 signiﬁcantly differentially expressed ECmiRNAs compared to un-
infected group (Sun et al., 2015). In case of renal ﬁbrosis (outcome of chronic kidney disease), administration of erythropoietin
markedly increases the expression of ECmiRNA miR-144 that was delivered to the injured renal ﬁbroblast through exosomes to
suppress tissue plasminogen activator (tPA) expression (Zhou et al., 2015). Furthermore, in vitro results demonstrated erythropoi-
etin stimulates cells to release exosomes containing higher amount of miR-144 which markedly suppress the expression of tPA in
cultured renal ﬁbroblast cells (Zhou et al., 2015).
Due to having speciﬁc expression pattern of exosome-coupled ECmiRNAs under altered physiopathological states, it is logical
to think these exosome-coupled ECmiRNAs are not passively released from the cells rather selectively loaded into exosomes to
serve speciﬁc functions. Although the biological function of exosomal ECmiRNA remains questionable in vivo, numerous
in vitro studies have demonstrated that ECmiRNAs enwrapped with exosomes can alter gene expression in the recipient cells.
For instance, exosome derived from hypoxic leukemia cells contain a subset of upregulated miRNAs including miR-210 which
my enhance tube formation in endothelial cells (Tadokoro et al., 2013). Another evidence for functional cell–cell transfer of
miRNAs through exosomes was found when nematode derived exosomes were co-cultured with mammalian cells (mice). Admin-
istration of such exosomes results transfer of nematode miRNAs which is responsible for the repression of Dusp1 gene (Buck
et al., 2014). Exosomes derived from biological ﬂuids have also been shown to be involved in the repression of target genes in
the recipient cells. When exosomes derived from follicular ﬂuid of competent oocytes, enriched with speciﬁc miRNAs, adminis-
trated to granulosa cells in vitor, it results signiﬁcant increase of those miRNAs in the recipient cells. Subsequently higher abun-
dance of speciﬁc miRNAs led suppression of their target genes (Sohel et al., 2013).
Release of ECmiRNA Through Microvesicles
Microvesicles (MVs), also known as ectosomes and microparticles, are membrane bound vesicles that differ from exosomes
based on their mechanism of release, biogenesis and biophysical properties, including size and surface markers. While exosomes
are the product of endocytic recycling pathway (inward budding), MVs are directly shed from plasma membrane through out-
ward budding and ﬁssion of membrane vesicles. Therefore, MVs contain much similar lipid contents as the plasma membrane
of their parent cells and the surface protein markers of MVs are largely dependent on the membrane of their origin (Lee et al.,
2012). Release of MVs can take place from resting cells, however, upon stimulation the rate of secretion increases dramatically.
Compare to exosomes that released in a more constitutive way and produce more homogenous populations, MVs tend to consti-
tute more heterogeneous and larger population of vesicles, ranging from 100 to 1000 nm in diameter (Aharon et al., 2009; Chironi
et al., 2009). Many cell types are known to secrete MVs including some cancer cells (Castellana et al., 2009), neurons (Marzesco
et al., 2005) and many of the hematopoietic and vascular cell types including endothelial cells, dendritic cells and B cells (Shet,
2008).
Like exosomes MVs can carry variety of molecules including miRNAs. Initially MVs were considered as cellular waste, however
experimental evidence suggests that MVs can inﬂuence several biological pathways and functions for example cardiovascular dis-
orders, including atherogogenesis and thrombosis (Mack et al., 2000; Mause and Weber, 2010; Shantsila et al., 2010). The pres-
ence of miRNAs in microvesicles has now been reported from different cells including mesenchymal stem cell (Callis et al.,
2009), mast cells (Sheﬂer et al., 2010), cancer cells (Jaiswal et al., 2012), platelets (Hunter et al., 2008) and endothelial cells
(Skog et al., 2008). When miR-143-transfected human monocytic leukemia THP-1 cells were incubation in serum-free medium,
it signiﬁcantly released microvesicles containing chemically modiﬁed miR-143 (Akao et al., 2011). Furthermore, it has been
shown that embryonic stem cell derived microvesicles are miRNA enriched and they can transfer a subset of miRNAs to mouse
embryonic ﬁbroblasts in culture, suggesting that gene expression of neighboring cells might be affected by exosomal miRNA
that was released by embryonic stem cells (Yuan et al., 2009). These ﬁndings highly support that at least some ECmiRNAs are en-
gaged in cell–cell communication via microvesicles but still thorough investigation is needed to understand the mechanisms of
selective miRNA incorporation into MVs for release.
Release of ECmiRNA Through Apoptotic Bodies
Apoptosis is an essential cellular process to remove unnecessary cells from multicellular organisms. When cells undergo apo-
ptotic process, they release phosphatidylserine (PS) — exposed vesicles as blebs, commonly known as apoptotic bodies (ABs) or
apoptotic vesicles. The major difference between ABs and cell that released other vesicles is their size. ABs are largest among all
extracellular vesicles and their size reported to range from 1 to 5 μm in diameter (Turiák et al., 2011). Budding of MVs occurs
mainly during early apoptosis and in response to stress and stimuli, whereas ABs are formed in the late stages of this death pro-
cess of a cell. Membrane blebbing depends on the activity of Rho-associated coiled coil kinase 1 (ROCK1). Caspase-3 (CASP3), one
of the executioner enzymes of apoptosis, was shown to be involved in the activation of ROCK1 that induces a net increase in my-
osin light chain phosphorylation and subsequently induces membrane blebbing (Croft, 2005; van der Pol et al., 2012). ABs are
larger than MVs & exosomes and represent the compacted or condensed residues of the apoptotic cells (Belting and Wittrup,
2008; Beyer and Pisetsky, 2010). Like other extracellular vesicles, ABs can carry a variety of molecules including miRNAs,
mRNAs and fragment of DNA.
Although it was proposed several years ago that ABs carry nucleic acids (Holmgren et al., 1999), it was only few years ago that
it has been demonstrated that ABs contain miRNAs when Zernecke et al. showed endothelial cells released Abs enriched with
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et al., 2009). Furthermore, administration of ABs containing higher number of miR-126 reduces the manifestations of atheroscle-
rosis in mice, while miR-126-deﬁcient Abs have no such effect (Zernecke et al., 2009). Interestingly, when miR-126 was found to
be highly enriched only in ABs, lower abundance was reported in MVs (Hergenreider et al., 2012). Therefore, it is logical to spec-
ulate that speciﬁc release of ECmiRNAs into ABs may be possible under certain pathophysiological condition. However, it requires
further investigation to conﬁrm that the loading of miRNAs into apoptotic bodies are either speciﬁc & selective or whether they
are nonspeciﬁcally loaded into ABs in response to a certain stimulus. Nevertheless, we cannot overrule another possibility that
ECmiRNAs in ABs are by-products of dying cells and loading of these ECmiRNAs is a random process due to collapse of most bi-
ological pathways, which might be the main difference from exosome. Although the detection of miRNA within ABs is of interest,
there are very few studies investigating the role AB encapsulated miRNA mediated effects in neighboring cells and more studies
need to determine how speciﬁc miRNA secreted, recognized for up-take via this process.
Release of ECmiRNA Through High Density Lipoprotein
In addition to membrane vesicles enwrapped release from cells, ECmiRNAs have also been found to be released in association
with lipoprotein in extracellular ﬂuids. Lipoproteins, consist of a variety of lipids and proteins, are involved in the transportation
of steroids, triglycerols, cholesterol and fat-soluble vitamins to peripheral tissues from the liver via low density lipoprotein (LDL)
or removal via high density lipoprotein (HDL) (Babin and Gibbons, 2009). Due to their higher solubility and afﬁnity to bind water
insoluble materials, lipoproteins are able to carry nucleic acids and often used as gene delivery agents (Kim et al., 2007).
The idea that ECmiRNAs may present in extracellular environment in association with lipoproteins, particularly with HDL,
arose when Lee et al., showed that hepatic siRNA could be effectively transferred to liver by reconstituted apolipoprotein A–I
(major functional protein in HDL) (Lee et al., 2009). Inspired by this publication Vickers et al. demonstrated for the ﬁrst time
that human HDL and LDL derived from blood plasma carry a considerable amount of miRNAs (Vickers et al., 2011). Unlike
exosomes or MVs which contain both miRNA and fragments of mRNA, highly puriﬁed HDLs are only rich in small non-coding
RNAs. A speciﬁc signature of miRNAs including miR-223, miR-105 and miR-106a was identiﬁed in HDL-miRNA complexes of fa-
milial hypercholesterolemia patients (Vickers et al., 2011). The authors further showed that delivery of these HDL bound miRNA
pool functionally downregulates their corresponding mRNA targets in cultured hepatocytes (Vickers et al., 2011), indicating the
functional relevance of these HDL coupled ECmiRNAs. In addition, it has recently been shown that transfer of HDL rich in miR-
223 signiﬁcantly increases the abundance of endogenous miR-223 concentration and subsequently suppresses the expression of
ICAM-1 (intracellular adhesion molecule 1) in endothelial cells and induces an anti-inﬂammatory action (Tabet et al., 2014). In-
terestingly, miR-223 is not transcribed in endothelial cells and HDL from miR-223−/− mice has no such effects (Tabet et al., 2014).
In another study, Niculescu et al., demonstrated that HDL derived from patients with coronary artery disease showed speciﬁc
miRNA signature compared to control (Niculescu et al., 2015). They found that signature of miR-486 and miR-92a associated
with HDL is distinct between vulnerable and stable coronary artery disease patients and suggested that, in addition to other
markers, these two ECmiRNAs can be used as a biomarker for vulnerable coronary artery disease (Niculescu et al., 2015). Collec-
tively, the results of these studies indicated that ECmiRNAs coupled with HDL might have biological relevance as they exhibit dis-
tinct expression pattern in relation to different pathological conditions with biomarker potential. Although HDL mediated release
and transport of ECmiRNAs is a new and exciting idea, the biggest challenge in this ﬁeld is to prove that these miRNAs are actively
and selectively released from donor cells and spontaneously taken up by recipient cells to mediate cell to cell communication.
Release of ECmiRNA Through Protein Complex
In addition to above mentioned pathways of release of ECmiRNAs, a handful number of studies reported that ECmiRNAs could
be released through binding with Argonaut protein families, particularly Argonaut 2 (Ago2). In mammalian organisms, functional
mature miRNAs generally bind with one protein complex called RNA-induced silencing complex (RISC) to regulate translation of
cellular mRNAs. Ago2 is one of the major components of RISC complex. In 2011, two independent research groups reported about
the presence of Ago2-miRNA complexes in cell culture media. Furthermore, western blot immunoassay shows that extracellular
miRNA ultraﬁltrated together with the Ago2 protein, a part of RNA-induced silencing complex, not associated with microvesicles
(Turchinovich et al., 2011). It has also been demonstrated that only 10% cell-free miRNAs were released in plasma through micro
vesicles whereas potentially 90% of the miRNAs in the circulation cofractionated with ribonucleo-protein complexes (Arroyo et al.,
2011). Size-exclusion chromatography has been used to exclude the micro vesicle contamination from protein complexes and
shows that most of the miRNA co-puriﬁed with non-vesicle-associated ribonucleo-protein complexes, only few miRNA, such as
miR-16 and miR-92a associated predominantly with micro vesicles (Arroyo et al., 2011). Although, the role of other RNA-
binding protein complexes, except Ago2, is presently unclear, collectively these results indicate that Ago2-protein complexes
might be involved with the delivery of miRNA from donor cell to recipient cells and facilitate cell–cell communications.
Potential Role of ECmiRNAs
Early ﬁndings that ECmiRNAs are enwrapped with exosomes or microvesicles, along with the evidences in vitro that they can
be transferred from one cell to another through exchange of exosomes (Hunter et al., 2008; Mitchell et al., 2008; Valadi et al.,
2007), provoked us to hypothesize that these vesicle-enwrapped ECmiRNAs may function as intercellular communication system
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pathophysiological conditions, it is not clear yet whether these ECmiRNAs are simply a waste product or they have any biological
functions. In the previous sections of this review, it has been discussed that ECmiRNAs can be existed in extracellular milieu with
association of various carriers. Since different types of ECmiRNAs are probably secreted as a result of different cellular processes,
thus it is important to differentiate them in order to understand their potential roles and functions.
It is clear from the deﬁnition; ABs are formed during apoptosis from dying cells. Although, Zernecke et al., showed the rele-
vance of ABs containing miR-126 with atherosclerosis manifestation in mice (Zernecke et al., 2009), it is very difﬁcult to believe
the biological viability of ABs enwrapped ECmiRNAs due to less number of reports that have been published since then. In the ﬁrst
study that reported the presence of protein bound ECmiRNAs, Arroyo et al., demonstrated that majority of ECmiRNAs are associ-
ated with Ago2 protein not with vesicle encapsulated (Arroyo et al., 2011). However, in contrast, we and others showed that ma-
jority of ECmiRNAs are concentrated in exosomes (Gallo et al., 2012; Noferesti et al., 2015; Sohel et al., 2013). Perhaps ECmiRNAs
coupled with Ago2 may be release from cells during necrosis or apoptosis (Turchinovich et al., 2011) and can be present in ex-
tracellular environment (Turchinovich and Burwinkel, 2012), but it is not known whether these Ago2-ECmiRNA complexes are
also released from viable cells and can be taken up by distant cells. Therefore, it leads us to speculate that ECmiRNAs incorporated
with ABs or coupled with Ago2 might solely be the waste product from dying cells or they could mediate a warning signal to the
organism about cellular dysfunction. However, it does not necessarily mean that AB or Ago2 coupled ECmiRNAs present in bio-
ﬂuid are always representing the cellular dysfunction or apoptosis.
On the other hand, exosomes and microvesicles are found to be released from viable cells, though it is unclear whether they
are not released from dying cells. Irrespective of cells of origin (either viable or dying), in vitro and in vivo experiments have
shown that they can be taken up by a variety of viable cells. Indeed, in vitro studies have shown that ECmiRNAs can be trans-
ferred from one cell to another through exosomes and in the recipient cells they can downregulate their target genes (Kogure
et al., 2011; Montecalvo et al., 2012; Sohel et al., 2013). These ﬁndings suggesting a potential role of exosomes enwrapped
ECmiRNAs that can mediate intercellular communication which might have huge impact. Recent example include, in myocardial
infarction model, when exosomes derived from mesenchymal stem cells were administrated to cardiac stem cells, it results an
improved migration, proliferation and angiogenic potency of cardiac stem cells (Zhang et al., 2016). Using in vitro model, Cui
et al., demonstrated that exosomes derived from mineralizing osteoblasts are able to enter bone marrow stromal cells and subse-
quently, promoting them towards osteoblast differentiation through enhancing the activity of β-catenin by altering the miRNA ex-
pression in recipient cells (Cui et al., 2015). Exosome and microvesicles derived from cigarette smock extract — induced primary
human bronchial epithelial cells contain a subset of ECmiRNA, which upon transfer promotes the myoﬁbroblast differentiation in
lung ﬁbroblasts (Fujita et al., 2015). Among the other examples, transfer of exosomes from stromal cells to breast cancer cells can
excite antiviral signaling and alter radiation sensitivity (Boelens et al., 2014), adriamycine-resistant breast cancer cells released
exosomes can transmit the resistance capacity to sensitive breast cancer cells by transferring speciﬁc miRNAs (Mao et al.,
2015), glioblastoma tumor cells released microvesicles can promote tumor growth by transferring mRNA, miRNA and protein
to the normal host cells or brain microvascular endothelial cells (Skog et al., 2008), extracellular vesicles from myeloid neoplasm
reduce the hematopoietic-supportive capacity of mesenchymal stromal cells via transfer of functional ECmiRNAs including miR-
7977 (Horiguchi et al., 2016), and alcohol exposed monocyte derived extracellular vesicles can excite naive monocytes to differ-
entiate into M2 macrophages by transferring ECmiRNAs including miR-27a (Saha et al., 2016).
In addition to orthodox role as posttranscriptional gene regulator, an unconventional role for ECmiRNAs as an activator of
RNA-sensing Toll-like receptor (TLR) has recently been demonstrated. ECmiRNA let-7 was shown to activate TLR7 in neurons
and induce neurodegeneration (Lehmann et al., 2012). Increased amount of let-7b was found in the cerebrospinal ﬂuid of
Alzheimer's disease. Interestingly, administration of extracellular let-7b into the cerebrospinal ﬂuid of wild type mice resulted
neurodegeneration (Lehmann et al., 2012). In another study Fabbri et al. showed that tumor derived exosomes contain miR-21
and miR-29a and upon transfer to immune cells they can bind and activate TLR7 and 8 which ultimately triggered a prometastatic
inﬂammatory response that may lead to tumor growth and metastasis (Fabbri et al., 2012).
Although many of the above experiments show exosome and microvesicles mediated transfer of ECmiRNAs and subsequent
genetic and phenotypic changes in the recipient cells, it has recently been challenged again whether the concentration of
exosomal ECmiRNAs in bio-ﬂuids is sufﬁcient to carry a translational repression of their target genes in the recipient cells
(Chevillet et al., 2014). Therefore, it became necessary to precisely determine if a subset of ECmiRNAs is speciﬁcally targeted to
transport to another cells via exosomes or microvesicles, gene expression patterns should be altered accordingly in the recipient
cells. Otherwise in this context, ECmiRNAs enwrapped with exosomes or microvesicles present in bio-ﬂuids would consider only
be a residual amount that may not have any biological relevance.Challenges in ECmiRNA Study
Despite the widespread interests in possible clinical application of ECmiRNAs, variations among the results have been observed
and hence the use of ECmiRNAs for a reproducible and reliable biomarker development still remains in infancy. Both pre-
analytical and analytical approaches, particularly choice of starting material, sample collection and processing related factors, de-
tection platform, and ﬁnally normalization and data analysis may contribute to the variation in results. Different factors that can
potentially contribute to the variations in results are shown in Fig. 3. In order to avoid the variability among the studies, a stan-
dardize strategy should be followed from sample collection to data analysis.
Fig. 3. Factors contributing variation in ECmiRNA study. Several factors including starting material, extraction method, detection platform, and data analysis may
directly or indirectly contribute to the variation in ECmiRNA result.
182 M.H. Sohel / Achievements in the Life Sciences 10 (2016) 175–186ECmiRNAs present in circulation or other biological ﬂuid can be quantiﬁed using different source of starting materials. For in-
stance, when ECmiRNAs are quantiﬁed from circulation, critical decision should be made — “whole blood or serum or plasma or
exosomes or microvesicles: which one is the best”? Whole blood should not be preferred, because cellular fraction (red and white
blood cells) will also contribute miRNAs and inﬂuence ECmiRNA analysis (Pritchard et al., 2012). On the other hand, if plasma is
used, EDTA will be the better choice to isolate plasma from whole blood and heparin should be avoided because it may inhibit
PCR ampliﬁcation. Serum can also be used as starting material for ECmiRNA study, however complete removal of cellular compo-
nent is mandatory for both plasma and serum since it could impair accurate ECmiRNA quantiﬁcation. Whether plasma or serum
used as starting material, which fraction will be used — exosome or microvesicles or ABs or HDL or protein associated miRNAs?
Exosomes are released from viable cells using a constitutive way of biogenesis and miRNA loading process (Pegtel et al., 2010),
therefore miRNA content in exosomes may reﬂect a speciﬁc physio condition of an organism. Whereas, due to nonspeciﬁc release
ABs, HDL & protein associated miRNAs may not be selected for biomarker study. Sample handling is another important issue.
Although, ECmiRNAs are found to be stable in harsh conditions like boiling, extremely low or high pH and multiple freezing
and thaw cycle, it is advisable that unnecessary freezing and thaw cycle should be avoided.
ECmiRNAs can be extracted from bio-ﬂuids using several extraction methods. Based on the extraction method, available com-
mercial kits can be divided in to two categories: phenol/chloroform-based extraction and column or bead based extraction meth-
od. Among the all available kits, miRNeasy Mini Kit (Qiagen) and mirVana PARIS kit (Life Technologies) produced highest yield of
total RNA extraction compared to TRIzol extraction (Sourvinou et al., 2013). Another obstacle for ECmiRNA study is the low
amount of total RNA present in bio-ﬂuids, which makes it very difﬁcult to precisely measure the quality and concentration of iso-
lated total RNA. NanoDrop spectrophotometer was used by many research groups to determine the quality and quantity of
ECmiRNAs extracted from bio-ﬂuid, however if the concentration is too low (less than 50 ng/μl) NanoDrop cannot measure the
concentration and sometime it remains undetected (Moret et al., 2013). Furthermore, in a disease state including cancer and car-
diovascular disease, higher amount of miRNAs can be released to circulation than their healthy counterpart. Therefore, it is advis-
able to use equal volume of starting material (serum, plasma or any other biological ﬂuid) instead of using same amount of total
RNA in order to have accurate results for biomarker detection study.
183M.H. Sohel / Achievements in the Life Sciences 10 (2016) 175–186Accurate quantiﬁcation of ECmiRNAs from bio-ﬂuids faced several challenges due to their low amount, short length and their
GC content. Nevertheless, several detection platforms have been used to detect ECmiRNAs. Quantitative reverse transcription po-
lymerase chain reaction (qRT-PCR) is one of the well-established methods for detecting cellular and ECmiRNA and considered as
golden standard. Among the available PCR based platform, both TaqMan TLDA microﬂuidic cards (Applied Biosystems) and
miRCURY LNA qPCR (Exiqon) exhibit high reproducibility between technical replicates and signiﬁcant correlation was observed
with the two platforms (Page et al., 2013). Hybridization based miRNA microarrays are available from several commercial com-
panies (Afﬁmetrix and Agilent) and able to analyze thousands of ECmiRNAs in one assay. Compare to ampliﬁcation based plat-
form (qRT-PCR), hybridization based microarrays are less expensive; however, it typically has lower speciﬁcity and dynamic
range. One of the major limitations for both qRT-PCR and Microarray is they can only detect the miRNA which are already
known and annotated in miRBase. On the other hand, ECmiRNAs quantiﬁed by miRNA-seq allow us to detect both novel and
known miRNAs. However, a standard protocol needs a large amount of starting material (1 μg RNA). To overcome this problem,
an adopted protocol has been proposed which will provide the opportunity to obtain miRNA-seq data as little as 5 ng of total RNA
extracted from bio-ﬂuid (Williams et al., 2013).
After overcoming all the challenges, once we obtained data, the ﬁnal challenge is to normalize and analyze the data. House-
keeping transcripts (U6 and SNORD) are generally used for the normalization of miRNA data obtained from cells or tissues, how-
ever, these housekeeping transcripts are inconsistently detected in bio-ﬂuids due to their high RNase sensitivity. If relatively large
number of miRNA is investigated, global normalization may use for data normalization. In global normalization method, a global
measure of the expression proﬁle of miRNAs, such as median or mean expression value, was used as data calibrator. However, this
approach is not suitable for small number of miRNAs or for individual miRNA assay data analysis. One of the widely accepted
normalization method is adding C. elegance spiked-in miRNAs during the denaturation procedure to normalize the biological
variability and used for data normalization (for detail please see (Moldovan et al., 2014; Tiberio et al., 2015). However, further
studies are necessary to ﬁnd out the systematic and best normalization method to reproducibly measure ECmiRNAs.
Concluding Remarks
Currently, we have sufﬁcient evidences to understand the biology of ECmiRNAs and to consider ECmiRNAs, retrieved from
serum/plasma or other biological ﬂuids, as a potential regulator of developmental processes and promising biomarker for several
diseases. However, inconsistent results in ECmiRNA study due to technical and experimental setup create so much controversy. It
is advisable to take several important points into account before designing studies to examine ECmiRNAs. One of the important
issues is low amount of miRNAs available in bioﬂuids or cell culture media; therefore, it is important to choose the right platform
where it allows analyzing ECmiRNAs with low volume of starting materials. Currently, several studies are improving the methods
to retrieve the highest amount of total RNA from the ﬂuid samples in order to proﬁle ECmiRNAs. Another important point is the
type of ECmiRNAs investigated such as exosomes, microvesicles, HDL or protein-associated miRNAs. As previously discussed, not
all means of ECmiRNA release and transportation are biologically viable; therefore, it may be useful to focus on single type of
ECmiRNAs, such as exosomal miRNAs or protein bound miRNAs, compared to total ECmiRNAs present in a biological ﬂuid. Indeed,
as an emerging ﬁeld ECmiRNA study still require a signiﬁcant technological advancement. Therefore, in order to obtain reliable
results from ECmiRNA studies, development of a standardized protocol is essential. Certainly, in near future, we will be able to
overcome the limitations in ECmiRNA study and it will greatly expand our understanding to developmental and disease biology
and perhaps may lead to development of new therapeutics.
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